A scoping review shows that several nonvalidated budget planning tools for randomized trials are available by Speich, B, Gloy, V, Schur, N, Ewald, H, Hemkens, L, Schwenkglenks, M, Briel, M

Systematic review on costs and resource use of randomized clinical trials shows a lack of transparent and comprehensive data by Speich, B, Von Niederhäusern, B, Schur, N, Hemkens, L, Fürst, T, Bhatnagar, N, Alturki, R, Agarwal, A, Kasenda, B, Pauli-Magnus, C, Schwenkglenks, M, Briel, M

Retrospective assessment of resource use and costs in two investigator-initiated randomized trials exemplified a comprehensive cost item list by Speich, B, Von Niederhäusern, B, Blum, CA, Keiser, J, Schur, N, Fürst, T, Kasenda, B, Christ-Crain, M, Hemkens, LG, Pauli-Magnus, C, Schwenkglenks, M, Briel, M

Resource use, costs, and approval times for planning and preparing a randomized clinical trial before and after the implementation of the new Swiss human research legislation by Speich, B, Schur, N, Gryaznov, D, Von Niederhäusern, B, Hemkens, L, Schandelmaier, S, Amstutz, A, Kasenda, B, Pauli-Magnus, C, Ojeda-Ruiz, E, Tomonaga, Y, McCord, K, Nordmann, A, Von Elm, E, Briel, M, Schwenkglenks, M, MARTA Study Group, ASPIRE Study Group